Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNEFER C SUTTON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790776276
CMS profile
35506
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$137.60

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $137.60 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $118.52 1
Organon LLC $19.08 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNEFER C SUTTON

NPI 1790776276 · CMS profile ID 35506

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $137.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $118.5202/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002105183 CMS
Organon LLC $19.0802/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046796385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $25.00 1
PY2023 $137.60 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $10,213.20 3
PY2024 Principal investigator $25,917.10 4
PY2023 Principal investigator $79,360.24 21
PY2022 Principal investigator $137,134.84 242
PY2021 Principal investigator $139,829.55 300
PY2020 Principal investigator $92,369.23 83
PY2019 Principal investigator $165,436.14 99

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $13,500.00 12/30/2020 Non-covered Recipient Entity
VIP TRIALS
M18-969 No dispute reported 06/30/2026 721203677
Principal investigator 1 AbbVie Inc. $3,495.20 12/30/2020 Non-covered Recipient Entity
VIP TRIALS
M16-283 No dispute reported 06/30/2026 721203679
Principal investigator 1 Novo Nordisk AS $366.75 12/22/2020 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 742420407
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201987
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201993
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201997
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202001
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202005
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202009
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202011
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202017
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202021
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202025
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 12/21/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737202031
Principal investigator 1 AbbVie Inc. $817.65 12/01/2020 Non-covered Recipient Entity
VIP TRIALS
M14-702 No dispute reported 06/30/2026 721198435
Principal investigator 1 Novo Nordisk AS $733.50 11/24/2020 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 742420405
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 11/18/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199033
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 11/18/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199037
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/18/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199041
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/18/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199045
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 11/04/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737197854
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 11/04/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737197859
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/04/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737197863
Principal investigator 1 AbbVie Inc. $4,274.55 11/02/2020 Non-covered Recipient Entity
VIP TRIALS
M14-702 No dispute reported 06/30/2026 721193953
Principal investigator 1 Novo Nordisk AS $4,258.66 10/29/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420401
Principal investigator 1 Novo Nordisk AS $325.00 10/29/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420403
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195117
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195121
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195125
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195129
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195133
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195137
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195141
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195145
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195149
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195153
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195159
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/12/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195163
Principal investigator 1 Esperion Therapeutics, Inc. $597.60 10/07/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195101
Principal investigator 1 Esperion Therapeutics, Inc. $210.60 10/07/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195105
Principal investigator 1 Esperion Therapeutics, Inc. $210.60 10/07/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195109
Principal investigator 1 Esperion Therapeutics, Inc. $210.60 10/07/2020 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195113
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/01/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194975
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/01/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194981
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/01/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194983
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/01/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194989
Principal investigator 1 Novo Nordisk AS $2,086.29 09/24/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420395
Principal investigator 1 Novo Nordisk AS $1,000.00 09/24/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420397
Principal investigator 1 Novo Nordisk AS $3,047.33 09/24/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420399
Principal investigator 1 AbbVie Inc. $330.75 07/02/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M16-283 No dispute reported 06/30/2026 721174691
Principal investigator 1 AbbVie Inc. $377.60 06/30/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M14-702 No dispute reported 06/30/2026 721173613
Principal investigator 1 AbbVie Inc. $711.45 06/01/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M16-283 No dispute reported 06/30/2026 721169075
Principal investigator 1 Novo Nordisk AS $2.99 06/01/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420391
Principal investigator 1 Novo Nordisk AS $23.46 06/01/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420393
Principal investigator 1 AbbVie Inc. $377.60 05/28/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M14-702 No dispute reported 06/30/2026 721168383
Principal investigator 1 Novo Nordisk AS $5,026.45 05/28/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420355
Principal investigator 1 Novo Nordisk AS $2.99 05/27/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420383
Principal investigator 1 Novo Nordisk AS $23.46 05/27/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420385
Principal investigator 1 Novo Nordisk AS $2.99 05/14/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420387
Principal investigator 1 Novo Nordisk AS $23.46 05/14/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420389
Principal investigator 1 AbbVie Inc. $4,787.55 05/04/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M16-283 No dispute reported 06/30/2026 721164879
Principal investigator 1 AbbVie Inc. $2,267.80 04/30/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M14-702 No dispute reported 06/30/2026 721164091
Principal investigator 1 Novo Nordisk AS $75.00 04/27/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420363
Principal investigator 1 Novo Nordisk AS $2,938.45 04/23/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420353
Principal investigator 1 Novo Nordisk AS $2.99 04/10/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420365
Principal investigator 1 Novo Nordisk AS $23.06 04/10/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420367
Principal investigator 1 Novo Nordisk AS $3,770.10 03/24/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420351
Principal investigator 1 Novo Nordisk AS $23.06 03/10/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420361
Principal investigator 1 Novo Nordisk AS $23.06 03/02/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420359
Principal investigator 1 AbbVie Inc. $1,863.70 02/28/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M16-283 No dispute reported 06/30/2026 721152557
Principal investigator 1 AbbVie Inc. $2,963.55 02/28/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M14-702 No dispute reported 06/30/2026 721153579
Principal investigator 1 Novo Nordisk AS $3,029.88 02/25/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420349
Principal investigator 1 Novo Nordisk AS $23.06 02/20/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420357
Principal investigator 1 Novo Nordisk AS $8,830.63 01/28/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420345
Principal investigator 1 Novo Nordisk AS $1,000.00 01/28/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420347
Principal investigator 1 AbbVie Inc. $4,703.60 01/24/2020 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD
M16-283 No dispute reported 06/30/2026 721146797
Principal investigator 1 Novo Nordisk AS $23.06 01/20/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420373
Principal investigator 1 Novo Nordisk AS $2.99 01/20/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420375
Principal investigator 1 Novo Nordisk AS $23.06 01/20/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420377
Principal investigator 1 Novo Nordisk AS $9.99 01/14/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420369
Principal investigator 1 Novo Nordisk AS $23.06 01/14/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420371
Principal investigator 1 Novo Nordisk AS $9.99 01/06/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420379
Principal investigator 1 Novo Nordisk AS $23.06 01/06/2020 Non-covered Recipient Entity
PRIMECARE MEDICAL GROUP
NN9535-4506 No dispute reported 06/30/2026 742420381